Sibutramin-containing medicines: Suspension of marketing authorisation because of increased risk for cardiovascular events
2010.01.25
Active substance: sibutramin
The BfArM wishes to inform the public that the suspension of marketing authorisation for sibutramin-containing medicines is considered necessary by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA).
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN